Telix Pharmaceuticals (TLX) Invested Capital (2023 - 2025)

Telix Pharmaceuticals (TLX) posted quarterly Invested Capital of $405.0 million for Q4 2025, little changed year-on-year from $403.1 million in Q4 2024, and little changed on a QoQ basis from $403.1 million in Q4 2024.

Telix Pharmaceuticals (TLX) Invested Capital (2023 - 2025) Analysis & Trends

Telix Pharmaceuticals (TLX) has reported Invested Capital for 3 consecutive years, with $405.0 million the latest figure, recorded in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Invested Cap. (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.96 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 116.14 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Telix Pharmaceuticals 3.55 Bn 3.41 Bn - 405.02 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 405.02 Mn
Dec 31, 2024 403.12 Mn
Dec 31, 2023 137.41 Mn